Celldex Therapeutics, Inc.
CLDX
$30.45
$1.916.69%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -63.91% | -45.73% | -32.88% | -23.45% | -11.62% |
| Total Depreciation and Amortization | 6.39% | 8.53% | 7.97% | 6.93% | 5.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 64.10% | 68.03% | 51.64% | 17.23% | 4.76% |
| Change in Net Operating Assets | 165.08% | 153.76% | -295.06% | -542.31% | -260.46% |
| Cash from Operations | -33.70% | -13.71% | -53.25% | -43.69% | -47.06% |
| Capital Expenditure | -41.43% | -19.68% | -59.20% | -16.68% | -5.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 173.48% | 137.20% | 132.10% | 114.80% | -177.22% |
| Cash from Investing | 172.06% | 136.61% | 131.57% | 114.37% | -174.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.46% | -99.78% | -99.71% | -99.15% | 102.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.46% | -99.78% | -99.71% | -99.15% | 102.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.97% | -102.37% | -235.69% | -260.68% | -219.93% |